Men with enlarged prostates treated with Nymox's fexapotide show profoundly lower incidence of surgeries in long-term crossover study; shares jump 76%

• Micro cap Nymox (NYMX +76.1%) zooms up on more than a 10x surge in volume in response to its announcement of positive results from a long-term Phase 3 study evaluating lead drug fexapotide in men with benign prostate hyperplasia (BPH) (enlarged prostate). The new data applies to the blinded crossover group who initially received placebo injections and then transitioned to either fexapotide or conventional BPH treatments. The aim of the study was to compare the rates of subsequent surgeries in the groups.
• The results showed that patients who crossed over to fexapotide experienced an 82 - 95% reduction in the number of surgeries during the following 2 - 3 years compared to those who crossed over and received conventional approved BPH therapies (p<0.0001).
• The encouraging results build on the positive long-term data reported two months ago that showed men with BPH treated with fexapotide had a much lower rate of prostate cancer compared to the general male population.
• Fexapotide (NX-1207) is administered directly into the prostate via a transrectal injection that does not require anesthesia or sedation.
• Previously: Nymox's lead product candidate reduces incidence of prostate cancer in long-term study; shares up 29% (June 22)